[From NIHR: National Institute for Health and Care Research]

We have awarded £1 million in funding to a first of its kind technology that’s being trialled to address threatened miscarriage.

Currently, over 150,000 women in the UK experience threatened miscarriage a year. If approved, the device would become the world’s first drug-device combination to treat threatened miscarriage and could help save the NHS £236 million per year in avoidable costs from the use of leaky progesterone pessaries.

Created by the team at Calla Lily Clinical Care, the device called Callavid delivers a dose of progesterone via a small, tampon-shaped device, improving progesterone delivery, preventing leakage and ensuring better absorption.

Thanks to our funding, the device will move to its first in-person trials.

Read more ➡️ https://www.nihr.ac.uk/news/new-trial-test-device-treating-threatened-miscarriage